The Sapience pipeline is more than a roadmap—it’s a testament to our mission to transform the treatment of hard-to-treat cancers. With SPEARs™ advancing through clinical trials, we are delivering new tomorrows where they’re needed most.
| Program/Target | Indication(s)/Settings | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| ST316 β-catenin (Wnt pathway) |
Phase 2: Colorectal Cancer | |||||
| Lucicebtide (ST101) C/EBPβ | Phase 2: Glioblastoma | |||||
| Lucicebtide C/EBPβ | rGBM Window-of-Opportunity Sub-Study †* | |||||
| Lucicebtide C/EBPβ | ndGBM Window-of-Opportunity Sub-Study * (ComboTx) | |||||
| JunAP cJun (AP1 complex) | Solid and heme | |||||
| FoxAP FOXP3 | Solid and heme (ComboTx) | |||||
| ST316 β-catenin (Wnt pathway) |
| Phase 2: Colorectal Cancer |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| Lucicebtide (ST101) C/EBPβ |
| Phase 2: Glioblastoma |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| Lucicebtide C/EBPβ |
| rGBM Window-of-Opportunity Sub-Study †* |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| Lucicebtide C/EBPβ |
| ndGBM Window-of-Opportunity Sub-Study * (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| JunAP cJun (AP1 complex) |
| Solid and heme |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| FoxAP FOXP3 |
| Solid and heme (ComboTx) |
Discovery IND-Enabling Phase 1 Phase 2 Phase 3 |
| Program/Target | Indication(s)/Settings | Discovery | IND-Enabling | Phase 1 | Phase 2 | Phase 3 |
|---|
†FDA Fast Track Designantion *FDA Orphan Drug Designation